Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-ATMPs for Malignant Pleural Effusion
NCT02657460Phase 2Unknown
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methotrexate in malignant pleural effusion (MPE). Primary endpoint: Pleural effusion volume at 4 weeks. Status: unknown.
02
Drugs
methotrexate
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT02657460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657460.